Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.
Novartis presented new findings from the largest global survey to date of people with psoriasis, showing many do not achieve the treatment goal of clear skin or even believe it is a realistic goal. Patients also report that they face discrimination, humiliation, and mental illness, according to the research presented at the European Academy of Dermatology and Venereology (EADV) Congress.
The Philippine Academy of Clinical and Cosmetic Dermatology (PACCD) celebrated its 13th Annual Convention at EDSA Shangri-La, Manila on October 6-8, 2016. With the theme “Practical Dermatology: New Concepts and Innovative Technology,” local and international dermatologists participated in sessions and workshops on innovative practical dermatology.
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, may help reduce the symptoms of atopic dermatitis, according to the results of two randomized, double-blind, placebo-controlled, phase III trials.